News

More than just dry eyes

Ophthalmology Times is pleased to announce Evan Warner, MD, of the University of Wisconsin, as the third-place winner of the publication’s 2014 Resident Writer’s Award Program, sponsored by Allergan. Dr. Warner’s submission is featured here.

A foldable, hydrophobic acrylic IOL embedded with a small-aperture mask provided excellent visual acuity across all distances in patients who underwent monocular implantation after cataract surgery and was not associated with any visual symptoms that may occur with other presbyopia-correcting IOLs.

A prospective, randomized trial of treatment for diabetic macular edema finds similar vision improvement with intravitreal bevacizumab (Avastin, Genentech) and an intravitreal dexamethasone implant (Ozurdex, Allergan), but differences in other endpoints.

A retinal surgeon describes a new scleral buckling device which requires less surgical dissection, has a one or two-stitch fixation, is applicable to treat pathology over 4 clock hours in any quadrant, and which can be removed in the office 3 to 4 weeks after insertion.

An examination of the advancements made in drug therapy this past year includes ocular surface therapy, the approval of an anti-inflammatory mydriatic agent, and several dry eye drugs.

With a wide array of IOL options available to their foreign colleagues, U.S. ophthalmologists eagerly await the approval and availability of additional lenses.

Not all orbital fractures need to be repaired, and not all fractures need to be repaired early after the patient sustains an insult. However, early repair of orbital factures can be beneficial for some patients. Ferreting out who those patients involves some special consideration.